Associate Director, Medical Science Liaison

Responsibilities

• Identify, build, and maintain strong relationships with Key Opinion Leaders (KOLs), clinicians, and research leaders within the assigned region.
• Provide scientific education regarding disease state awareness and clinical data to support genomic-guided therapy decisions.
• Facilitate advanced education regarding products in the hematology, oncology, and pathology communities through scientific exchange and presentations.
• Coordinate involvement in national, regional, and local scientific forums, including symposia and tumor boards.
• Develop scientific materials such as slide decks, white papers, monographs, and clinical synopses.
• Integrate with Medical Affairs to organize scientific advisory boards and coordinate clinical trials.
• Gather market intelligence on competitor products and emerging developments.
• Respond to complex scientific and genomic inquiries from healthcare providers.
• Travel within the assigned territory 70%+ of the time.

Requirements

• Master's degree in health sciences, medicine, nursing, or genetics with 7+ years of MSL experience in life sciences (diagnostic, biotech, or pharma).
• OR an advanced scientific/healthcare degree (PhD, PharmD, DNP) with 4+ years of MSL experience in life sciences.
• Proven experience in Oncology.
• Willingness to travel 70%+ of the working time.

Preferred Qualifications

• PhD, MD, DNP, or PharmD.
• Advanced subject matter expertise in cancer genomics and biomarker/therapeutic development.
• Existing KOL relationships within the assigned territory.
• Expertise in market analysis, market access strategy, and territory planning.
• Familiarity with CLIA, LDT, and AdvaMed Guidelines.
• Deep understanding of cancer patient management algorithms and the clinical utility of molecular tests.

About the Company

Foundation Medicine is a global, patient-focused precision medicine company delivering high-quality, transformative diagnostic solutions in cancer and other diseases. Our mission is to ensure that each patient receives the right treatment for their unique cancer through genomic-guided therapy.